 Studies in Asia of unresectable hepatocellular cancer HCC demonstrated that sorafenib could be administered safely at 400mg twice a day BID when initiated 14 days following radioembolization RE. However, the ideal sequence of RE and sorafenib may not be completely elucidated, the two treatments given concurrently may be more effective than the sequential approach studied in the Asian trials. Preclinical models have demonstrated that sorafenib acts synergistically with radiation, increasing apoptosis. Furthermore, case reports suggest profound responses in patients who have received sorafenib concurrent with transarterial radioembolizatoin TARE as evidenced by improvement in symptoms, 80 decrease in alpha fetoprotein AFP, and conversion from unresectable to resectable. Sorafenib concurrent with TARE may take advantage of the synergistic relationship between the two therapies and prove to be a more effective treatment strategy than sequential administration of TARE and sorafenib. 